Seeking Alpha

Wedbush hikes target on Receptos

  • Market chatter suggests Wedbush is out with a price target hike to $44 (from $26) for Receptos (RCPT -0.8%).
  • Rationale: Optimism for RPC1063's potential in IBD,
  • BMO was out with a similarly bullish call ($41 target) earlier this month, highlighting development of RPC1063 in Relapsing Multiple Sclerosis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: